Lysosomal dysfunction and inflammatory responses caused by beta-glucocerebrosidase 1 (GBA1) mutations, a risk factor of PD, can be normalized by LRRK2 inhibitors [215, 216]. Here, LRRK2 is linked to Parkinson disease.